1NWS
CBIO

1 North Wealth Services’s Crescent Biopharma CBIO Stock Holding History

1 North Wealth Services’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-120
Closed -$2.52K – 277
2025
Q1 		$2.52K Hold
120
– – ﹤0.01% 223
2024
Q4 		$2.99K Buy
+120
New +$3.27K ﹤0.01% 59

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

1 North Wealth Services's CBIO Position: Q2 2025 in Review

1 North Wealth Services sold out of Crescent Biopharma (CBIO) in Q2 2025, closing a stake of 120 shares — an estimated $2.52K sold.

1 North Wealth Services first reported a position in CBIO in Q4 2024 and held it in 2 quarters. The position peaked at $2.99K in Q4 2024. 30 funds tracked by Wall St. Rank hold CBIO as of Q2 2025.

  • 1 North Wealth Services reported no remaining Crescent Biopharma position as of Q2 2025 after selling out during the quarter.
  • 1 North Wealth Services sold 120 Crescent Biopharma shares in Q2 2025, an estimated $2.52K.
  • 1 North Wealth Services first reported a position in Crescent Biopharma in Q4 2024 and held it in 2 quarters.
  • 1 North Wealth Services's Crescent Biopharma position peaked at $2.99K in Q4 2024.
  • 30 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2025.

Based on 1 North Wealth Services's 13F filing for Q2 2025, filed 23 Jul 2025.